Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, That Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy
Access StatusFull text of the requested work is not available in DASH at this time ("dark deposit"). For more information on dark deposits, see our FAQ.
Chen, Po C.
Gaisina, Irina N.
El-Khodor, Bassem F.
Kozikowski, Alan P.Note: Order does not necessarily reflect citation order of authors.
MetadataShow full item record
CitationLu, Bo, David P. Hoogerheide, Qing Zhao, Hengbin Zhang, Zhipeng Tang, Dapeng Yu, and Jene A. Golovchenko. 2013. “Pressure-Controlled Motion of Single Polymers through Solid-State Nanopores.” Nano Letters 13 (7) (July 10): 3048–3052. doi:10.1021/nl402052v.
AbstractThe discovery of upregulated glycogen synthase kinase-3 (GSK-3) in various pathological conditions has led to the development of a host of chemically diverse small molecule GSK-3 inhibitors, such as BIP-135. GSK-3 inhibition emerged as an alternative therapeutic target for treating spinal muscular atrophy (SMA) when a number of GSK-3 inhibitors were shown to elevate survival motor neuron (SMN) levels in vitro and to rescue motor neurons when their intrinsic SMN level was diminished by SMN-specific short hairpin RNA (shRNA). Despite their cellular potency, the in vivo efficacy of GSK-3 inhibitors has yet to be evaluated in an animal model of SMA. Herein, we disclose that a potent and reasonably selective GSK-3 inhibitor, namely BIP-135, was tested in a transgenic Δ7 SMA KO mouse model of SMA and found to prolong the median survival of these animals. In addition, this compound was shown to elevate the SMN protein level in SMA patient-derived fibroblast cells as determined by Western blot, and was neuroprotective in a cell-based, SMA-related model of oxidative stress-induced neurodegeneration.
Citable link to this pagehttp://nrs.harvard.edu/urn-3:HUL.InstRepos:33373176
- FAS Scholarly Articles